A. Geerts, W. F. Arts, H. Stroink, E. Peeters, O. Brouwer et al., Course and outcome of childhood epilepsy: A 15-year follow-up of the Dutch Study of Epilepsy in Childhood, Epilepsia, vol.51, pp.1189-97, 2010.

A. Chowdhury and M. J. Brodie, Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate, Epilepsy Research, vol.119, pp.62-68, 2016.

D. Putignano, A. Clavenna, R. Campi, A. Bortolotti, I. Fortino et al., Antiepileptic drug use in Italian children over a decade, Eur J Clin Pharmacol, vol.73, pp.241-249, 2017.

C. J. Landmark, E. Rytter, and S. I. Johannessen, Clinical use of antiepileptic drugs at a referral centre for epilepsy, Seizure, vol.16, pp.356-64, 2007.

A. Malerba, C. Ciampa, D. Fazio, S. Fattore, C. Frassine et al., Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy, Epilepsy Research, vol.91, pp.273-82, 2010.

L. Forsgren, E. Beghi, A. Õun, and M. Sillanpää, The epidemiology of epilepsy in Europe -a systematic review, European Journal of Neurology, vol.12, pp.245-53, 2005.

U. Kramer, Y. Nevo, M. Y. Neufeld, A. Fatal, Y. Leitner et al., Epidemiology of epilepsy in childhood: A cohort of 440 consecutive patients, Pediatric Neurology, vol.18, pp.46-50, 1998.

C. Chiron,

, Rev Prat, vol.62, pp.1395-400, 2012.

M. Duchowny and A. S. Harvey, Pediatric epilepsy syndromes: an update and critical review, Epilepsia, vol.37, issue.1, pp.26-40, 1996.

R. Savica, E. Beghi, G. Mazzaglia, F. Innocenti, O. Brignoli et al., Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years, European Journal of Neurology, vol.14, pp.1317-1338, 2000.

C. Johannessen-landmark, H. Fossmark, P. G. Larsson, E. Rytter, and S. I. Johannessen, Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population, Epilepsy Research, vol.95, pp.51-60, 2011.

R. Ackers, F. Besag, A. Wade, M. L. Murray, and I. Wong, Changing trends in antiepileptic drug prescribing in girls of child-bearing potential, Arch Dis Child, vol.94, pp.443-450, 2009.

K. J. Meador, P. Penovich, G. A. Baker, P. B. Pennell, E. Bromfield et al., Antiepileptic drug use in women of childbearing age, Epilepsy Behav, vol.15, pp.339-382, 2009.

J. M. Nicholas, L. Ridsdale, M. P. Richardson, M. Ashworth, and M. C. Gulliford, Trends in antiepileptic drug utilisation in UK primary care 1993-2008: Cohort study using the General Practice Research Database, Seizure, vol.21, pp.466-70, 2012.

, Valproate and its derivatives : risk of abnormal pregnancy outcomes -Dear Doctor Letter, 2014.

J. Weston, R. Bromley, C. F. Jackson, N. Adab, J. Clayton-smith et al., Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child, Cochrane Database of Systematic Reviews, 2016.

R. Bromley, The treatment of epilepsy in pregnancy: The neurodevelopmental risks associated with exposure to antiepileptic drugs, Reproductive Toxicology, vol.64, pp.203-213, 2016.

J. Christensen, T. K. Grønborg, M. J. Sørensen, D. Schendel, E. T. Parner et al., Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism, JAMA, vol.309, pp.1696-703, 2013.

U. Deshmukh, J. Adams, E. A. Macklin, R. Dhillon, K. D. Mccarthy et al., Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine, Neurotoxicology and Teratology, vol.54, pp.5-14, 2016.

, New prescription and delivery conditions for valproate and its derivatives linked to the risks associated to their use during pregnancy -Dear Doctor Letter, 2015.

T. B. Mole, R. Appleton, and A. Marson, Withholding the choice of sodium valproate to young women with generalised epilepsy: Are we causing more harm than good?, Seizure, vol.24, pp.127-157, 2015.

F. Raguideau, M. Mezzarobba, M. Zureik, A. Weill, P. Ricordeau et al., Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin, Pharmacoepidemiol Drug Saf, vol.24, pp.526-559, 2015.

E. Polard, E. Nowak, A. Happe, A. Biraben, E. Oger et al., Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study, Pharmacoepidemiol Drug Saf, vol.24, pp.1161-1170, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01198646

, Exposition à l'acide valproïque et ses dérivés au cours de la grossesse en France de, Agence nationale de sécurité du médicament et des produits de santé, 2007.

W. O. Pickrell, A. S. Lacey, R. H. Thomas, R. A. Lyons, P. Smith et al., Trends in the first antiepileptic drug prescribed for epilepsy between, Seizure, vol.23, pp.77-80, 2000.

I. Tsiropoulos, A. Gichangi, M. Andersen, L. Bjerrum, D. Gaist et al., Trends in utilization of antiepileptic drugs in Denmark, Acta Neurologica Scandinavica, vol.113, pp.405-416, 2006.

C. Johannessen-landmark, P. G. Larsson, E. Rytter, and S. I. Johannessen, Antiepileptic drugs in epilepsy and other disorders-A population-based study of prescriptions, Epilepsy Research, vol.87, pp.31-40, 2009.

S. A. Hollingworth and M. J. Eadie, Antiepileptic drugs in Australia, Pharmacoepidem Drug Safe, vol.19, pp.82-91, 2010.

A. Geerts, W. F. Arts, H. Stroink, E. Peeters, O. Brouwer et al., Course and outcome of childhood epilepsy: A 15-year follow-up of the Dutch Study of Epilepsy in Childhood, Epilepsia, vol.51, pp.1189-97, 2010.

A. Chowdhury and M. J. Brodie, Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate, Epilepsy Research, vol.119, pp.62-68, 2016.

D. Putignano, A. Clavenna, R. Campi, A. Bortolotti, I. Fortino et al., Antiepileptic drug use in Italian children over a decade, Eur J Clin Pharmacol, vol.73, pp.241-249, 2017.

C. J. Landmark, E. Rytter, and S. I. Johannessen, Clinical use of antiepileptic drugs at a referral centre for epilepsy, Seizure, vol.16, pp.356-64, 2007.

A. Malerba, C. Ciampa, D. Fazio, S. Fattore, C. Frassine et al., Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy, Epilepsy Research, vol.91, pp.273-82, 2010.

, Age*, median (quartiles), vol.5, pp.1-9

. Lti-=-epilepsy,

N. Cmuc, 3) Hospitalization for epileptic seizure ? , n (%) 14449 (27,7) 17497 (28,6) Initiation of an antiepileptic treatment ?, vol.30, p.15719, 19780.

, Number of ATC classes experimented by child ?, Annual density of prescription of AED ? , median (quartiles), vol.11, pp.7-12

, 6) Diazepam 16227 (31,1) 20529 (33,5) Lamotrigine 8813 (16,9) 7493 (12,2) without VPA 25539 (49,0) 26525 (43,3) >50% of prescriptions in monotherapy with VPA 19019 (36,5) 25743 (42,0) >50% of prescriptions in polytherapy without VPA 2030 (3,9) 2219 (3,6) >50% of prescriptions in polytherapy with VPA 2877, Taking AED treatment ** , n (%) Sodium valproate 27508, vol.52, p.3611

, ? Parameter calculated over the study period, 2010.

, ? Parameter calculated over the period of prescription (from the first prescription until the last prescription identified over the study period

, LTI denotes long-term illness status which gives entitlement to full health care reimbursement, CMUC Complementary Universal Health Insurance status, which provides information on the patients' socio-economic level, AED antiepileptic drug